Definitions of Breakthrough Disease and Second-Line Agents

Neurologic Clinics

Volumn 29, Issue 2, 2011, Pages 411-422

  Marriott, James J ^a   O'Connor, Paul W ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Breakthrough disease; Cyclophosphamide; Management; Mitoxantrone; Multiple sclerosis; Natalizumab

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; IMMUNOMODULATING AGENT; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB;

BREAKTHROUGH DISEASE; DISEASE COURSE; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; OFF LABEL DRUG USE; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK BENEFIT ANALYSIS; STANDARDIZATION; TREATMENT FAILURE; TREATMENT RESPONSE;

DRUG APPROVAL; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79952856754     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2010.12.005     Document Type: Review

References (75)

1. Rudick R.A., Polman C.H. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009, 8:545-559.
2. Polman C.H., O'Connor P.W., Havrdova E., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910.
3. Rudick R.A., Stuart W.H., Calabresi P.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
4. Niino M., Bodner C., Simard M.L., et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006, 59:748-754.
5. Hutchinson M., Kappos L., Calabresi P.A., et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009, 256:405-415.
6. Biogen Idec Study evaluating Rebif, Copaxone, and Tysabri for active multiple sclerosis (SURPASS) 2000, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda (MD), Available at:, NLM Identifier: NCT01058005. Accessed June 15, 2010. http://clinicaltrials.gov/ct2/show/NCT01058005.
7. Phillips J.T., O'Connor P.W., Havrdova E., et al. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology 2006, 67:1717-1718.
8. Hellwig K., Schimrigk S., Fischer M., et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol 2008, 65:656-658.
9. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006, 354:924-933.
10. Food and Drug Administration. FDA drug safety communication: risk of progressive multifocal leukoencephalopathy (PML) with the use of Tysabri (natalizumab) [updated 02/05/2010] In: FDA.gov [Internet]. Silver Springs (MD): U.S. Food and Drug Administration. Available at: Accessed June 15, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm.
11. Crespi M.D., Ivanier S.E., Genovese J., et al. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun 1986, 136:521-528.
12. Hartung H.P., Gonsette R., Konig N., et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial. Lancet 2002, 360:2018-2025.
13. Krapf H., Morrissey S.P., Zenker O., et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005, 65:690-695.
14. Ghalie R.G., Edan G., Laurent M., et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002, 59:909-913.
15. Ghalie R.G., Mauch E., Edan G., et al. A study of therapy-related leukemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002, 8:441-445.
16. EMD Serono, Inc Novantrone (mitoxantrone) for injection concentrate. [Product Monograph] Available at:, Accessed June 1, 2010. http://www.novantrone.com/assets/pdf/novantrone_prescribing_info.pdf.
17. Marriott J.J., Miyasaki J.M., Gronseth G., et al. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 74:1463-1470.
18. Weiner H.L., Cohen J.A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002, 8:142-154.
19. Perini P., Calabrese M., Rinaldi L., et al. The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 2007, 62:183-190.
20. Weiner H.L., Hauser S.L., Dawson D.M., et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991, 337:1033-1034. [letter].
21. Noseworthy J.H., Vandervoort M.K., Penman M., et al. Cyclophosphamide and plasma exchange in multiple sclerosis. Lancet 1991, 337:1540-1541. [letter].
22. Noseworthy J.H., Ebers G.C., Roberts R. Cyclophosphamide and MS. Neurology 1994, 44:579. [letter].
23. Weiner H.L., Orav E.J., Hafler D.A., et al. Cyclophosphamide and MS. Neurology 1994, 44:580-581. [letter].
24. Hauser S.L., Dawson D.M., Lehrich J.R., et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983, 308:173-180.
25. Weiner H.L., Mackin G.A., Orav E.J., et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993, 43:910-918.
26. The Canadian Cooperative Multiple Sclerosis Study Group The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991, 337:441-446.
27. Atkins H., Freedman M. Immunoablative therapy as a treatment for aggressive multiple sclerosis. Neurol Clin 2005, 23:273-300.
28. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008, 7:626-636.
29. Burt R.K., Loh Y., Cohen B. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009, 8:244-253.
30. Fagius J., Lundgren J., Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler 2009, 15:229-237.
31. Krasulová E., Trneny M., Kozák T. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010, 16:685-693.
32. Sorensen P.S., Mellgren S.I., Svenningsson, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009, 8:519-529.
33. Cohen J.A., Imrey P.B., Calabresi P.A., et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 2009, 72:535-541.
34. Ravnborg M., Sørensen P.S., Andersson M., et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurol 2010, 9:672-680.
35. Kappos L., Radue E.-W., O'Connor P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401.
36. Cohen J., Barkhof F., Comi G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010, 362:402-415.
37. Giovannoni G., Comi G., Cook S., et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010, 355:1124-1140.
38. The CAMMS223 Trial Investigators Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786-1801.
39. Genzyme Comparison of alemtuzumab and Rebif® efficacy in multiple sclerosis, study two (CARE-MS II) 2000, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda (MD), Available at:, NLM Identifier: NCT00530348. Accessed June 15, 2010. http://clinicaltrials.gov/ct2/show/NCT00548405.
40. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
41. Genentech A. Study of the efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis 2000, ClinicalTrials.gov [Intranet], National Library of Medicine (US), Betheseda (MD), Available at:, NLM Identifier: NCT00676715. Accessed June 15, 2010. http://clinicaltrials.gov/ct2/show/NCT00676715.
42. Goodin D.S., Frohman E.M., Hurwitz B., et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007, 68:977-984.
43. Polman C.H., Bertolotto A., Deisenhammer F., et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010, 9:740-750.
44. Calabresi P.A., Giovannoni G., Confavreux C., et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007, 69:1391-1403.
45. Teitelbaum D., Brenner T., Abramsky O., et al. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler 2003, 9:592-599.
46. Ransohoff R.M. Natalizumab for multiple sclerosis. N Engl J Med 2007, 356:2622-2629.
47. O'Connor P.W. Use of natalizumab in multiple sclerosis patients. Can J Neurol Sci 2010, 37:98-104.
48. Karussis D., Biermann L.D., Bohlega S., et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006, 13:61-71.
49. Wiendl H., Toyka K.V., Rieckmann P., et al. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008, 255:1449-1463.
50. Boster A., Edan G., Frohman E., et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol 2008, 7:173-183.
51. Bashir K., Buchwald L., Coyle P.K., et al. MS patient management: optimizing the benefits of immunomodulatory therapy. Int J MS Care 2002, 4:3-7.
52. Freedman M.S., Patry D.G., Grand'Maison F., et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004, 31:157-168.
53. Freedman M.S., Forrestal F.G. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008, 14:1234-1241.
54. Ruiz-Pena J.L., Duque P., Izquierdo G. Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria. BMC Neurol 2008, 8:3.
55. Serono E.M.D. A prospective study looking at the use of Rebif® in subjects with clinically isolated syndrome (CIS-ON) 2000, ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda (MD), Available at:, NLM Identifier: NCT00287079. Accessed June 15, 2010. http://clinicaltrials.gov/ct2/show/NCT00287079.
56. Gajofatto A., Bacchetti P., Grimes B., et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Mult Scler 2009, 15:50-58.
57. Putzki N., Kollia K., Woods S., et al. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol 2009, 16:424-426.
58. Putzki N., Yaldizli O., Mäurer M., et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 2010, 17:31-37.
59. Putzki N., Yaldizli O., Bühler R., et al. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland. Eur Neurol 2010, 63:101-106.
60. Krysko KM, O'Connor PW. Comparability of randomized controlled versus observational studies: findings from the Toronto observational study of natalizumab in multiple sclerosis [abstract P05.081]. In the 62nd Annual Meeting of the American Academy of Neurology. Toronto, April 10-17, 2010.
61. Mikol D.D., Barkhof F., Chang P., et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008, 7:903-914.
62. O'Connor P., Filippi M., Arnason B., et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009, 8:889-897.
63. Jeffery D.R., Chepuri N., Durden D., et al. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 2005, 11:296-301.
64. Correale J., Rush C., Amengual A., et al. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta. J Neuroimmunol 2005, 162:173-183.
65. Benesova Y., Stourac P., Beranek M., et al. Mitoxantrone therapy in rapidly worsening multiple sclerosis. Bratisl Lek Listy 2005, 106:141-143.
66. Cocco E., Marchi P., Sardu C., et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007, 13:975-980.
67. Buttinelli C., Clemenzi A., Borriello G., et al. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Eur J Neurol 2007, 14:1281-1287.
68. Khan O.A., Zvartau-Hind M., Caon C., et al. Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler 2001, 7:185-188.
69. Perini P., Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol 2003, 250:834-838.
70. Patti F., Cataldi M.L., Nicoletti F., et al. Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001, 71:404-407.
71. Reggio E., Nicoletti A., Fiorilla T., et al. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients: twenty-four months follow-up. J Neurol 2005, 252:1255-1261.
72. Smith D.R., Weinstock-Guttman B., Cohen J.A., et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler 2005, 11:573-582.
73. Gladstone D.E., Zamkoff K.W., Krupp L., et al. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 2006, 63:1388-1393.
74. Krishnan C., Kaplin A.I., Brodsky R.A., et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008, 65:1044-1051.
75. Makhani N., Gorman M.P., Branson H.M., et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009, 72:2076-2082.